The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence.
about
Glioma Stem Cells: Signaling, Microenvironment, and TherapyDo relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysisPreferential Association of Lissencephaly-1 Gene Expression with CD133+ Glioblastoma Cells.Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.Malignant clinical features of anaplastic gliomas without IDH mutation.Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma.Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.The novel role of pyrvinium in cancer therapy.Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study.CPEB4 interacts with Vimentin and involves in progressive features and poor prognosis of patients with astrocytic tumors.High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma.Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications.Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.Prognostic implication of NOTCH1 in early stage oral squamous cell cancer with occult metastases.
P2860
Q26765854-E6690F95-A07E-4E95-8D32-E40412FDB2F7Q26865791-450DB87B-3B1C-4A31-934A-4EE6D4889E88Q33776755-F12E023F-408E-4889-9F5B-7846173729C8Q35573268-9E964D87-85E6-499F-864A-9343F3C7C8F5Q35788726-F97312A5-E4FA-40E2-B5CC-AC319A9FEF50Q35823287-C249EC52-12F6-4971-A157-B68D3B1EC0E6Q37441567-B2B02B00-868F-422B-98AB-D9BFF3047AB6Q38266427-F853B577-03AE-4927-8E8E-98B0AC201A27Q38684406-1B3A318B-24EC-4A19-8E0C-B5F1A15197FBQ38769659-B1FB804E-5647-46CA-BFAF-A1CA395386E2Q38945218-2589E050-CC2F-41C9-8B94-AC8E5E8E67B0Q40930271-3803FD77-62F4-42E3-A4EA-581D43708900Q47136308-B3F24F3D-3EAB-48BA-BEEE-1B1332CAF89CQ47579926-BC092002-0448-4FC9-9737-ECAC7BB1D214Q48376550-6A64CBEE-5EF8-4A3D-AA93-6B3E73935D13Q48451292-E878F803-B145-4EC1-8793-31F71DF175E1Q50230082-F4520EB3-1D0E-43BD-BDB0-98168ECACA42
P2860
The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The expression status of CD133 ...... imary glioblastoma recurrence.
@en
The expression status of CD133 ...... imary glioblastoma recurrence.
@nl
type
label
The expression status of CD133 ...... imary glioblastoma recurrence.
@en
The expression status of CD133 ...... imary glioblastoma recurrence.
@nl
prefLabel
The expression status of CD133 ...... imary glioblastoma recurrence.
@en
The expression status of CD133 ...... imary glioblastoma recurrence.
@nl
P2093
P2860
P356
P1433
P1476
The expression status of CD133 ...... rimary glioblastoma recurrence
@en
P2093
Chikashi Ishioka
Hiroyoshi Suzuki
Ichiyo Shibahara
Masayuki Kanamori
Mika Watanabe
Ryuta Saito
Takashi Watanabe
Teiji Tominaga
Toshihiro Kumabe
Yoji Yamashita
P2860
P304
P356
10.1093/NEUONC/NOT066
P577
2013-05-07T00:00:00Z